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Introduction 
Body Dysmorphic Disorder (BDD) is a serious health issue, 
classified according to DSM-V as an obsessive-compulsive-related 
disorders (OCRD)1,2 and characterized by an overwhelming concern 
of perceived somatic defects that to other people appear slight or 
even nonexistent. In addition, a preoccupation with this perceived 
defect, typically accompanied by time-consuming behaviors such 
as repeated mirror-watching and ineffective attempts to ‘improve’ 
or “cover” the defect (i.e. usage of cosmetic products of several 
kinds), leads to significant distress and functional impairment e.g. 
high rates of occupational impairment, with avoidance behaviors 
leading to unemployment, social dysfunction and isolation.3 BDD 
most commonly has an onset between 15 and 30 years of age and 
frequently, there is comorbid depression, anxiety, and sometimes 
also other OCRDs. A serious concern is that individuals with BDD 
often suffer an increased risk of suicide with rates of suicidal ideation 
ranging from 17%–77%, and suicide attempts from 3%–63%.4‒6 
The bodily areas in target of the preoccupations are the skin, hair, 
nose, eyes, eyelids, mouth, lips, jaw, and chin, although it may involve 
any part of the body, or multiple body parts at the same time. With 
regard to the obsessive thinking, this typically includes perceived or 
slight defects or flaws on the face, asymmetrical or disproportionate 
face or body features, including wrinkles, scars, thinning of hair, acne, 
vascular markings, and pallor, or ruddiness of skin texture. 
Albeit BDD is common and a serious health threat, surprisingly 
little attention has been paid to recognition of the disorder, and to 
improving diagnosis, treatment and increase research and it is 
only through dedicated research to BDD, and not in the context of 
OCDR research, that our knowledge will increase to improve early 
identification and treatment. This review serves to put focus on what 
is known about treatment of BDD to date. 
Clinical trials in BDD
There are few clinical trials that have been done in BDD and 
most have been open label trials. Only one of the trials have been 
a randomized, double-blind, placebo-controlled,7 which included 67 
individuals and showed that fluoxetine, a selective serotonin reuptake 
inhibitors (SSRI), was more efficacious than placebo. The open label 
trials all found that SSRIs are commonly effective in BDD.8‒11 In a 
blinded crossover trial found clomipramine, a serotonin reuptake 
inhibitor (SRI), to be more effective than desipramine12 in BDD.
Since most patients with BDD receive pharmacotherapy of some 
kind13 and since BDD is often chronic, thereby requiring long-
term treatment,13 it would also be important to investigate risk of 
relapse following discontinuation of efficacious medication in BDD. 
Phillips et al., investigated this in 100 BDD patients and found that 
continuation-phase escitalopram delayed time to relapse, and that 
fewer escitalopram-treated subjects relapsed than did placebo-treated 
subjects. The severity score of BDD significantly improved during 
6 additional months of escitalopram treatment following an acute 
treatment response. In addition, more than one-third of escitalopram-
treated subjects experienced further improvement.3 
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Abstract
Background: Body Dysmorphic Disorder (BDD) is a common, often severe disorder 
characterized by appearance concerns and a preoccupation with thinking and behaviors 
related to this concern. Population-based investigations have found a prevalence of BDD of 
1.5-2% in the general population. The first-line of treatment for BDD is usually Selective 
Serotonin Reuptake Inhibitors (SSRI) which often alleviates suicidal thinking, and act 
to protect against further aggravation of suicidal thinking. For delusions, antipsychotic 
treatment is usually required. This review provides an update on guidelines and 
pharmacological treatment studies of BDD including recommendations for management 
and treatment. 
Material and method: A narrative review of the current literature. 
Results: A presentation of guidelines, some key studies and recommendations for 
pharmacological treatment of BDD. 
Conclusion: Only one placebo controlled efficacy trial has been done finding that fluoxetin 
is superior to placebo in treatment of BDD. Several open trials support this finding and a 
randomized trial have found SSRI to reduce time to relapse. Clinical experiences suggest 
SSRI may reduce risk of suicidality. In severe cases, add-on treatment of second generation 
anti-psychotics may alleviate psychotic symptoms. 
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International guidelines for pharmacological 
treatment of BDD
According to NICE guidelines,14 it states that for adults with OCD 
which includes BDD:
1. In the initial treatment of adults with Obsessive Compulsive 
Disorder (OCD), low intensity psychological treatments (including 
exposure and response prevention; ERP) (up to 10 therapist hours 
per patient) should be offered if the patient’s degree of functional 
impairment is mild and/or the patient expresses a preference for a 
low intensity approach. 
a. Low intensity treatments include: brief individual CBT 
(including ERP) using structured self-help materials brief 
individual CBT (including ERP) by telephone group CBT 
(including ERP) (note, the patient may be receiving more than 
10 hours of therapy in this format). 
b. Mild BDD: Adults with OCD with mild functional impairment 
who are unable to engage in low intensity CBT (including 
ERP), or for whom low intensity treatment has proved to be 
inadequate, should be offered the choice of either a course of 
an SSRI or more intensive CBT (including ERP) (more than 10 
therapist hours per patient), because these treatments appear to 
be comparably efficacious. 
c. Moderate BDD: Adults with OCD with moderate functional 
impairment should be offered the choice of either a course of 
an SSRI or more intensive CBT (including ERP) (more than 10 
therapist hours per patient), because these treatments appear to 
be comparably efficacious. 
d. Severe BDD: Adults with OCD with severe functional 
impairment should be offered combined treatment with an SSRI 
and CBT (including ERP).
The first steps in successful pharmacotherapy of BDD: Essential 
in successful treatment of BDD is to establish a proper rapport. As a 
psychiatrist, it is important to be prepared for asking questions about 
the patient’s concerns and to provide a proper expression of empathy 
for the patient’s suffering. Frequently, patients feel completely 
overwhelmed and hopeless and desperate about their symptoms, and 
to explain that there are reasons for hope is crucial in the first steps of 
establishing a therapeutic alliance with a patient.
Before initiating any treatment of any disorder, a comprehensive 
and thorough diagnostic work-up is required. This includes 
establishing trust, performing a medical interview, followed by a 
mental status examination, a somatic examination and making use 
of BDD diagnostic instruments a) to exclude other diagnoses and b) 
find support for the BDD diagnosis. There are no specific laboratory 
tests. Since the purpose of this review is to describe pharmacological 
treatment of BDD, a reference is made to other reviews dedicated to 
the diagnostic work-up.15
It is also equally important to educate the patient about what BDD 
is and what kind of therapeutic options there are for patients with 
BDD. Both written information but primarily describing what BDD 
is, how frequent it is, what it causes to patients, what the risks are 
with not treating BDD is part of a proper groundwork before initiating 
pharmacotherapy. Crucial is not to focus on how the patient looks. 
The patient’s beliefs are the patient’s own and they usually cannot 
be convinced otherwise. For example, expressing whatever opinion 
yourself may have on the patient’s looks will lead to a risk of lack of 
trust which may continue and develop into an interruption in treatment 
both early but also later on. Regarding psychoeducation, it is helpful 
to present BDD as a disorder of perception, an exaggerated focus on 
details and repetitiveness in thoughts and behaviors. It is also essential 
not to encourage patients to engage in surgical or dermatological 
interventions. Usually, these treatments, including dental and other 
cosmetic treatments are never helpful to relieve the BDD concerns. 
Instead, it is appropriate to encourage patients to try medicines but 
also to become involved in cognitive behavioral therapy or similar 
approaches.
First line of treatment for BDD
SSRI medications are first line treatments for BDD, also delusional 
BDD. There are several randomized double-blind studies (Table 
1) as well as NICE practice guidelines14 and Cochrane review to 
support this approach.16 SSRIs do improve symptoms of BDD such 
as depressiveness and core BDD symptoms, but not only that, also 
psychosocial functioning is improved by SSRIs. However, it should 
be recalled in this context that there is no approved treatment for 
BDD, which relate partly to lack of interest from Pharmaceutical 
industry and furthermore that BDD, in spite of being prevalent, is 
usually under-recognized and underdiagnosed. SSRIs are approved 
for obsessive-compulsive disorder (OCD), with which BDD shares 
some features such as the preoccupation of appearance concerns. 
SSRI treatments have, in both open-label and controlled studies, 
been shown to significantly alleviate BDD-related preoccupation, 
distress, and compulsive behaviors.3,12,17 In addition, depressive 
symptoms, anger-hostility, somatic symptoms, anxiety, impairment 
in psychosocial functioning, mental health-related quality of life and 
BDD-related insights significantly improved in most of the studies.3,11 
A few studies did also explore the effects of SSRI on suicidal ideation 
finding that compared to placebo, it improved and provided protective 
effects against a worsening of suicidal ideation.18
Which SSRI to choose and dosing
There are currently no studies to indicate that any of the SSRIs 
are better and more efficacious than the other. Usually, escitalopram 
or fluoxetine are chosen since they are the most well studied SSRIs 
in BDD. In addition, they are usually well-tolerated, also at the dose 
level which is recommended for treatment of BDD. A second choice 
may be more noble SSRIs such as sertraline but also, especially when 
there is an insufficient effect of SSRIs, a switch to clomipramine may 
be explored as an alternative.
There is currently no dose finding studies in BDD. However, 
clinically it is well-established that to be able to relieve patients from 
BDD-related symptoms, much similar to treatment of OCD, higher 
doses than what is standard for treatment of depression is required. 
Sometimes, double or triple the standard anti-depressive dose is 
required with SSRIs for treatment of BDD, and more occasionally, 
patients may benefit from normal doses of SSRI.
Usually, a standard titration rate may be adopted, and it is only 
in the very advanced and intensively ill patients that a more rapid 
up titration of the SSRI dose may be recommended. That means 
that in usual, it takes at least 2 to 3 months to reach an appropriate 
BDD dosage level with SSRIs. And it is wise to recall that BDD in 
principle in the majority of cases requires high to very high doses of 
SSRIs. Thereby, a treatment failure or inadequate response to one of 
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recommended SSRIs, at a dosage level which is twice as high as the 
anti-depressive should not discourage the psychiatrist and the patient 
to try even higher doses.
When introducing the patient to pharmacological treatment with 
SSRIs, it may be proposed to try this medication for a period of time 
in order to have the patient consider whether this is something for him/
her to approve for his/her BDD symptoms. In these kinds of situations, 
usually at least 3 months of treatment should be described as the basis 
for exploring effectiveness of SSRIs in BDD. In fact, beneficial is to 
aim for at least 4 months if the patient is able to agree to this.
Table 1 Examples of clinical trials in adult individuals suffering from BDD1 
Study Drug Design Sample Size
Duration of 
exposure, 
Mean Dose 
(mg/day) 
Results* References
SRI or SSRI as 
Monotherapy
     
Clomipramine 
vs. 
desipramine 
R, DB, controlled, CO, MTA n=29
16 weeks 
(8 weeks 
on each 
medication)
Clomipramine more effective 
than desipramine; response 
rate 65% vs. 35%
Hollander E 
et al.12
   CMI:  138±87   
   CMI:  147±80   
   12 weeks   
Fluoxetine ine 
vs. placebo R, DB, PC parallel group trial, ITT n=67 77.7±8.0
Fluoxetine more effective than 
placebo; response rate 53% vs. 
18%; effect  size: d=.70
Phillips KA 
et al.7
   CMI: 138±87   
   CMI: 147±80   
Escitalopram 
vs. placebo
Initially open-label trial with escitalo pram; responders 
to open-label treatment were randomized to double-
blind continuation treatment with escitalopram vs. 
placebo for 6 months, ITT 
n=100 in 
open label 
phase; 58 in 
DB phase
14 week 
open label 
phase
Open-label trial: BDD 
symptoms improved; 67% of 
subjects (ITT) and 81% PP.
Phillips KA.17
   26.2±7.2
Time to relapse longer with 
escitalopram than placebo  
   
6-month 
randomized 
phase
Relapse proportions: 18% 
for escitalopram vs. 40% for 
placebo.
 
   28.7±4.6
In continuation phase, BDD 
improved in escitalopram-
treated subjects; 36% of 
subjects further improved.
 
SRI 
Augmentation 
Studies
     
Pimozide vs. 
placebo R, DB, PC ,parallel-group trial, ITT N=28 8 weeks No differences Phillips KA.
19
   2mg   
*Studies used a definition of treatment response set to at least 30% or higher in the total score of the primary outcome, which most often was BDD-YBOCS 
(if not otherwise mentioned).  
Abbreviations: BDD-YBOCS, yale-brown obsessive-compulsive scale modified for body dysmorphic disorder; DB, double blind; ITT, Intent to Treat; MTA, 
minimum treatment analysis; PC, placebo controlled; PP, per protocol; R, randomized; SRI, serotonin reuptake inhibitor; SSRI, selective serotonin reuptake 
inhibitor
1Clinical trials with memantine, oxytocine and d-cycloserine has also been done, according to clinicaltrials.gov (19 November 2019).
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Table 2 Clinical experience with dosing of Selective Serotonin-Reuptake Inhibitors and tricyclic antidepressant as first-line treatment of BDD 
Medication Starting Dose*
Common 
maximum dose
Occasional 
maximum Dose**
SSRI   60
Citalopram (Celexa) 20 40 120
Escitalopram (Lexapro) 10 30 450
Fluoxetine (Prozac) 20 60 100
Fluvoxamine (Luvox) 50 200 400
Paroxetine (Paxil) 20 60  
Sertraline (Zoloft) 50 200 250 *** 
Dibenzazepine-derivative tricyclic 
antidepressant    
Clomipramine (Anafranil) 25  150*** 
*After initiation, follow dose escalation scheme according to prescription guidelines
**According to the American Psychiatric Association’s Practice Guidelines for Obsessive-Compulsive Disorder
***Blood sampling for plasma levels of clomipramine and metabolite, desmethylclomipramine should be monitored (measured 12 hours after dosing; aim at 
<500ng/mL to minimize risk of adverse events)
SSRI augmentation strategies
In quite a few of instances, an augmentation strategy may 
be indicated. Especially in cases where there have been suicidal 
ideations or depressive symptoms, or delusions, a combination of 
SSRI and other pharmacotherapies may be indicated. According to 
US recommendations, buspirone to be added to SSRIs may be well-
tolerated and an appropriate choice for many patients with BDD. A 
few studies have indicated that adding buspirone to SSRIs may further 
improve the efficacy and reduce BDD-related symptoms.
There is as yet only one double-blind, randomized, placebo-
controlled tired of augmenting SSRI treatment with an antipsychotic, 
in this case, pimozide in a mean dosage of 2 mg per day.19 The 
including criteria was that the patient with BDD had not responded 
to SSRIs after 12 weeks of appropriate dosing of a monotherapy. The 
primary reason that pimozide was used was that it had been indicated 
for somatic delusions, including BDD. However, it had never before 
been tried appropriately. The other reason is that pimozide usually is 
effective as an augmenter to SSRIs in the treatment of OCD. Pimozide 
turned out to be more efficacious than placebo as an add-on to SSRI 
although the effect size was rather small.19 Later case series and 
clinical experience indicate that adding on olanzapine or quetiapine or 
even aripiprazole to SSRIs may be helpful in instances where SSRI as 
monotherapy is providing an insufficient response.20,21
Several other pharmacotherapies have been suggested such as 
the previously described clomipramine, but also venlafaxine and 
levetiracetam.12,22‒24 In the acute phase and where symptoms are very 
severe, benzodiazepines may be tried in the short term. It is however 
important not to prescribe these medications, for the longer term, due 
to tolerance development and dependence.
Treatment of severe BDD with delusions
There are rather few studies that have explored the effects of 
treatment directed at delusions in BDD, but the studies done have 
consistently found that patients with delusional BDD benefit from 
SSRI as monotherapy, and that both delusional BDD patients and 
non-delusional BDD patients responded equally well to SSRIs.11,25 
Should this be insufficient, standard treatment for delusions would 
include the addition of antipsychotic medicines, and in view of the 
benefits of SSRIs, one may argue that anti-psychotic medicines acting 
on serotonergic receptors such as quetiapine and olanzapine would be 
first choice. 
Hurdles to treatment 
Several studies have revealed that BDD often is undertreated with 
pharmacotherapy. In a study by Phillips, only 20% of all included had 
received BDD-focused treatment despite a majority of the patients 
believed that BDD was their major problem.6 Other studies have also 
indicated an inadequate dosing and inappropriate selection of medical 
treatments for BDD.
One reason for this may be that many patients wait for long times 
before they seek help with BDD related issues. One study investigating 
reasons for this found that patients were too ashamed (frequency 34%), 
believing that only plastic surgery or dermatologic treatment would 
help (32%), or had a feeling that a clinician would not understand 
their appearance concerns (21%), or fear of side effects of medication 
(13%), or simply not feeling ready for treatment of BDD (7%), or 
lacking access to specialized care (6%;).27 This study by Buhlmann27 
was an Internet survey of 172 individuals with self-reported BDD, 
while an observational naturalistic study by Phillips et al.26 including 
interviews with 151 individuals diagnosed with BDD found that the 
primary reason for not having been treated with pharmacotherapy was 
that they had never been offered this treatment in spite of a proper 
diagnosis of BDD. Under diagnosing of BDD is a major issue as well 
as not offering proper treatment when BDD is being diagnosed.
Combining SSRI with cognitive behavioral therapy
Usually, medication is combined with some form of supportive or 
better cognitive behavioral therapy for BDD. In milder cases of BDD, 
both CBT alone while also SSRI alone may be equally effective. 
However, in moderate to severe BDD, pharmacotherapy is essential 
both to enable psychotherapeutic interventions but also to alleviate the 
often devastating symptoms of BDD and the risk of suicidal ideation.
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Conclusion
1. The following treatment recommendations should be considered 
for BDD.
2. Establish a proper rapport with the patient.
3. Provide psycho education both in written and verbal form.
4. Explain the effects and side effects of various treatment options 
with pharmacotherapy.
5. First line of treatment is SSRIs.
6. A titration phase of at least 3 up to maybe 4 or even longer months 
is usually required since dosing for BDD is usually similar to 
treatment of OCD, more than double the standard anti-depressive 
doses using SSRIs.
7. A treatment trial of 3 to 4 months is recommended before 
switching to other treatment options. For severe BDD including 
delusions, a combination of SSRI with antipsychotics in a low 
dose, or buspirone may be tried.
8. A continued treatment, sometimes for several years, is common 
when treating BDD.
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